About us

About us

The Company

Leading through biomanufacturing and chemical synthesis

Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and generic markets, integrating chemical synthesis and biological processes while always embracing the highest international safety, quality, and environmental standards.

With one of the longest track records of the API industry, having deep development expertise and a broad set of advanced technologies, we are the partner of choice which enables our client’s molecules to enter the market successfully

Olon has a global network of 11 manufacturing sites and 7 R&D centers across the globe. Thanks to our 2,300 employees, including 300 highly experienced and qualified R&D experts, we represent a highly innovative and reliable partner

At Olon, expertise and competent flexibility throughout the organization help build successful outcomes for our clients in custom chemical synthesis and microbial fermentation, while always maintaining the highest levels of safety, quality, and environmental compliance.

With our structured expertise in chemical synthesis and microbial biomanufacturing, we are one of the leading international players of API and HPAPI production. Our sites are equipped with multi-purpose, dedicated lines where we can produce at different levels of high containment, up to ultra-high-containment for high-potency and toxic products.
Our expertise is applied to the production of APIS for treatments used in many key therapeutic areas and for many breakthrough pharmaceutical products. We are leaders in the production of retinoids, antineoplastic, cardiovascular and metabolic diseases compounds, antibiotics and antivirals.


Challenge and innovate
the way to deliver science to improve
health of human beings.

Creative ideas and pathway for
Prompt and Sustainable solutions
in life science industry.


Olon Group adopts the Code of Ethics that establishes the principles and core values that govern and regulate operations at all levels, in all organizational areas, and in all the company’s operational and production locations. The Olon Code of Ethics is validated and signed by the Group Leadership Team.



Acquisition of:

  • Solchem Italiana
  • Laboratori Mag
  • Antibioticos

Highly specialized in microbial biomanufacturing, one of the most extensive experience of industrial microbial biomanufacturing in UE

  • OLON establishes the international footprint opening new offices in Shanghai and in USA
  • The Group is established, as merging of the acquired companies, and it is named Olon

Acquisition of:

  • INFA Group
    three further manufacturing facilities
  • Labochim, Sifavitor, Italy
  • Derivados Quimicos Spain

Acquisition of:

  • Ricerca Bioscience, USA
    Established as a carve out of the R&D centre
  • Capua Bioservices becoming one of the first companies in Europe producing with microbial biomanufacturing for third parties
  • Novartis API plant in Mahad, India
  • Opening Mumbai Offices